As few as one in ten people survive pancreatic cancer five years after their diagnosis — making it the most difficult cancer to survive. The survival rate five years after diagnosis is 6-14%, but ...

Fear of nuclear fallout has led to a novel therapeutic approach that could significantly extend the lives of individuals with ...

Recent positive lab confirmation of Smart mRNA functionality is a tremendous milestone for the Company. This marks a ...

Thanks to decades of sustained, predictable federal investments and increases in pancreatic cancer research, the research ...

The PAC-MANN test was able to differentiate — 98% of the time — between the blood of someone with pancreatic cancer and the ...

Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional ...

Several ASX-listed healthcare companies with low market caps are making strides in tackling cancer,  a leading cause of death ...

Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer ...

The study developed a noninvasive detection method based on serum protease activity, leveraging the increased protease activity in the peripheral blood of patients with PDAC. Researchers screened a ...

Pancreatic cancer is the 10th deadliest form of cancer in the United States, according to the National Cancer Institute.

In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three ...

A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease ...